NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 309 filers reported holding NOVOCURE LTD in Q1 2022. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,262,829 | +135.4% | 54,526 | +241.1% | 0.28% | +160.6% |
| Q1 2023 | $961,398 | -57.7% | 15,986 | -48.4% | 0.11% | -57.9% |
| Q4 2022 | $2,272,383 | +375.4% | 30,980 | +392.0% | 0.26% | +398.1% |
| Q3 2022 | $478,000 | -78.4% | 6,297 | -80.2% | 0.05% | -76.1% |
| Q2 2022 | $2,212,000 | +90.5% | 31,831 | +105.8% | 0.22% | +73.0% |
| Q4 2021 | $1,161,000 | -38.0% | 15,466 | -4.0% | 0.13% | -11.9% |
| Q3 2021 | $1,872,000 | +38.1% | 16,114 | +163.6% | 0.14% | +19.2% |
| Q2 2021 | $1,356,000 | +108.0% | 6,112 | +23.9% | 0.12% | +110.5% |
| Q1 2021 | $652,000 | – | 4,933 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |